Immunovia AB (1YR) AI Stock Analysis

1 Followers

Immunovia AB

(Frankfurt:1YR)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

PancreaSure adoptionGrowing use across 36 surveillance programs, with one-third ordering consistently, indicates meaningful clinical adoption rather than isolated testing. Broader utilization can strengthen physician confidence, support recurring test demand, and provide a foundation for expansion as additional centers and clinicians are targeted.

Negative Factors

Persistent unprofitabilityThe company has not yet demonstrated a scalable profit model despite recent revenue growth. Negative gross profit and deeply negative margins mean additional sales are not currently translating into earnings, while persistent losses could continue consuming capital and constrain investment in commercial expansion.

Immunovia AB (1YR) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 672.67K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.3
Beta (1Y): 109.46
Revenue Growth: 157.39%
EPS Growth: 65.73%
Country: Germany
Employees: 18
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Immunovia AB Business Overview & Revenue Model

Company Description

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic...

Immunovia AB Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|Next Earnings Date:Feb 11, 2027

Earnings Call SentimentPositive

The call was predominantly positive, with strong year-over-year revenue growth, accelerating PancreaSure adoption, progress toward reimbursement, lower operating losses and cash burn below prior guidance. These developments were offset by continued operating losses, limited reimbursement data, uncertain coverage timing, the absence of sales guidance and a highly dilutive rights issue required to fund operations into 2027.

Positive Updates

Accelerating PancreaSure Adoption

The company reported accelerating adoption in Q3 2026, with 36 high-risk surveillance programs now using the PancreaSure test, including leading institutions such as Memorial Sloan Kettering, Northwestern Medicine, Michigan Medicine, Stanford and Beth Israel Deaconess.

Negative Updates

Highly Dilutive Rights Issue

Management acknowledged that the approximately SEK 63 million rights issue is highly dilutive for shareholders and described the dilution as painful. The company apologized for needing another rights issue to fund operations into 2027.

Company Guidance

Management said Q3 cash burn was SEK 5 million per month, significantly below the previously discussed guidance of SEK 8 million to SEK 10 million per month; the rights issue is expected to raise approximately SEK 63 million before issue costs and compensation to the underwriters, with 80% secured, or approximately SEK 50 million, to fund operations through the second quarter of 2027, while TO 4 could potentially generate additional proceeds of SEK 31.7 million to fund operations into the third quarter 2027. The subscription period is November 9 to November 25 this year, and the warrant subscription period is April 19 to May 3, 2027. The company does not give sales guidance for 2026, expects to share preliminary insurance-payment data with potential U.S. commercialization partners in the fourth quarter, expects to talk to FDA again early in 2027, and is expanding PancreaSure to the other 2 dozen clinicians at SSGA.

Immunovia AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1YR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:DVYSR	66Neutral	SEK 1.08B	43.88	―	―	4.49%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:QLINEA	43Neutral	SEK 264.34M	-1.61	-48.10%	―	33.26%	90.73%
SE:ACARIX	42Neutral	SEK 200.96M	-5.09	-96.06%	―	40.61%	32.63%
SE:BIOVIC.B	41Neutral	SEK 89.52M	-1.30	-75.51%	―	56.06%	63.95%

* Healthcare Sector Average

Performance Comparison

DE:1YR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1YR	Immunovia AB	0.01	-0.00	-16.67%
SE:QLINEA	Q-linea AB	13.90	-11.22	-44.67%
SE:ACARIX	Acarix AB	0.16	-0.11	-40.37%
SE:BIOVIC.B	Biovica International AB Class B	0.32	-0.23	-41.30%
SE:DVYSR	Devyser Diagnostics AB	66.70	-46.90	-41.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Immunovia AB AI Stock Analysis